WuXi AppTec, a global leading pharmaceutical services company, kicked off the construction of its headquarter of central China region in Wuhan, capital of Hubei Province. With a total investment of 2 billion yuan, it is expected to reach target output around 2025.

  Sited in Optics Valley, the project is planned to be built on a total area of 205 mu. After completion, 50 high-level overseas Chinese talents, and 5,000 medical research and development personnel will be introduced to build it into the country's largest research and development service platform for new small-molecule drug.

  At the same time, the project will be closely integrated with emerging technologies such as artificial intelligence, machine learning, automation, and robotic to create a world's leading platform for medicinal chemistry and other emerging chemical technology.

  WuXi AppTec is a platform-based company that provides comprehensive and integrated new drug R&D and production services for global biomedical industry. It currently has 29 branches around the world and has provided R&D and production services for more than 4,100 partners from over 31 countries. Established in 2010, the Wuhan branch of WuXi AppTec is the first new drug R&D service platform to settle in Optics Valley Biolake. It currently has a 40,000-square-meter R&D base and employees of more than 2,300 people.

  (Source: en.hubei.gov.cn)